PIK3CG and neoplasm: A phase Ib clinical trial assessed the combination of taselisib with palbociclib in metastatic BC including a cohort of TNBC selected for activating PIK3 mutations and showed good treatment tolerability and promising preliminary anti-tumor activity [99].